HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Oramed Pharmaceuticals (NASDAQ:ORMP) from Buy to Neutral.
Benchmark Reiterates Buy on Quanex Building Prods, Maintains $31 Price Target
Benchmark analyst Reuben Garner reiterates Quanex Building Prods (NYSE:NX) with a Buy and maintains $31 price target.